Establishing Alkermes’ Leadership in Sleep Medicine

Today’s completion of the acquisition of Avadel Pharmaceuticals plc (Avadel) is a transformational step for our organization, marking the next phase of Alkermes’ evolution as we expand our capabilities and establish our position in sleep medicine. This moment represents not just growth, but alignment with our long‑term vision for the future of Alkermes. We are building an exciting neuroscience company, rooted in science and guided by patients.

Avadel is a recognized innovator in sleep medicine, focused on addressing unmet needs for patients living with narcolepsy. We look forward to gaining key insights from that experience and building on the team’s momentum. Members of both organizations are already working hard to integrate the important work of the two companies and to ensure continuity in day-to-day execution. Together, we are establishing a strong, nimble organization with deep experience in sleep medicine and leadership in the emerging field of orexin biology.

I’d like to express my thanks to our employees, whose support will be critical in ensuring a smooth transition over the next few months. 2026 is going to be a transformational year for Alkermes as we work together to bring important new innovations to people living with complex neurological and psychiatric disorders. 

Learn more